Effects of Prolastin C (plasma-derived alpha-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study)

American Journal of Cardiology

Volumn 115, Issue 1, 2015, Pages 8-12

  Abbate, Antonio ^a   Van Tassell, Benjamin Wallace ^a   Christopher, Sanah ^a   Abouzaki, Nayef Antar ^a   Sonnino, Chiara ^a   Oddi, Claudia ^a   Carbone, Salvatore ^a   Melchior, Ryan David ^a   Gambill, Michael Lucas ^a   Roberts, Charlotte Susan ^a   Kontos, Michael Christopher ^a   Peberdy, Mary Ann ^a   Toldo, Stefano ^a   Vetrovec, George Wayne ^a   Biondi Zoccai, Giuseppe ^b   Dinarello, Charles Anthony ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN CONCENTRATE; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE MB; PLACEBO; BIOLOGICAL MARKER; SERINE PROTEINASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; ACUTE HEART INFARCTION; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENTING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; OPEN STUDY; PATIENT COMPLIANCE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PILOT STUDY; PLASMA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; BLOOD; ELECTROCARDIOGRAPHY; METABOLISM; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; RETROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84915822743     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.09.043     Document Type: Article

References (12)

1. I.M. Seropian, S. Toldo, B.W. Van Tassell, and A. Abbate Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction J Am Coll Cardiol 63 2014 1593 1603
2. A. Abbate, M.C. Kontos, J.D. Grizzard, G.G. Biondi-Zoccai, B.W. Van Tassell, R. Robati, L.M. Roach, R.A. Arena, C.S. Roberts, A. Varma, C.C. Gelwix, F.N. Salloum, A. Hastillo, C.A. Dinarello, G.W. Vetrovec VCU-ART Investigators Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study) Am J Cardiol 105 2010 1371 1377
3. A. Abbate, B.W. Van Tassell, G. Biondi-Zoccai, M.C. Kontos, J.D. Grizzard, D.W. Spillman, C. Oddi, C.S. Roberts, R.D. Melchior, G.H. Mueller, N.A. Abouzaki, L.R. Rengel, A. Varma, M.L. Gambill, R.A. Falcao, N.F. Voelkel, C.A. Dinarello, and G.W. Vetrovec Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study Am J Cardiol 111 2013 1394 1400
4. B.W. Van Tassell, S. Toldo, E. Mezzaroma, and A. Abbate Targeting interleukin-1 in heart disease Circulation 128 2013 1910 1923
5. S. Toldo, I.M. Seropian, E. Mezzaroma, B.W. Van Tassell, F.N. Salloum, E.C. Lewis, N. Voelkel, C.A. Dinarello, and A. Abbate Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury J Mol Cell Cardiol 51 2011 244 251
6. E.C. Lewis Expanding the clinical indications for α(1)-antitrypsin therapy Mol Med 18 2012 957 970
7. M.B. Nienhuis, J.P. Ottervanger, M.J. de Boer, J.H. Dambrink, J.C. Hoorntje, A.T. Gosselink, H. Suryapranata, A.W. van't Hof Zwolle Myocardial Infarction Study Group Prognostic importance of creatine kinase and creatine kinase-MB after primary percutaneous coronary intervention for ST-elevation myocardial infarction Am Heart J 155 2008 673 679
8. S. Orn, C. Manhenke, T. Ueland, J.K. amås, T.E. Mollnes, T. Edvardsen, P. Aukrust, and K. Dickstein C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction Eur Heart J 30 2009 1180 1186
9. L.M. Biasucci CDC AHA CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper Circulation 110 2004 e560 e567
10. J. Loscalzo Pilot trials in clinical research: of what value are they? Circulation 119 2009 1694 1696
11. K. Viele, S. Berry, B. Neuenschwander, B. Amzal, F. Chen, N. Enas, B. Hobbs, J.G. Ibrahim, N. Kinnersley, S. Lindborg, S. Micallef, S. Roychoudhury, and L. Thompson Use of historical control data for assessing treatment effects in clinical trials Pharm Stat 13 2014 41 54
12. A. Abbate, F.N. Salloum, E. Vecile, A. Das, N.N. Hoke, S. Straino, G.G. Biondi-Zoccai, J.E. Houser, I.Z. Qureshi, E.D. Ownby, E. Gustini, L.M. Biasucci, A. Severino, M.C. Capogrossi, G.W. Vetrovec, F. Crea, A. Baldi, R.C. Kukreja, and A. Dobrina Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction Circulation 117 2008 2670 2683